News
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.
Swipe to discover more
-
VETFIRE™: bioMérieux launches cutting-edge equine infectious respiratory disease testing
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of VETFIRE™, a ready-to-use PCR kit that makes testing for equine infectious respiratory diseases easier and faster. -
Why participatory approaches for AMR matters to people and patient-centered action
Antimicrobial Resistance (AMR) is a term that is not widely recognised by many people globally. What’s even more concerning is that those who are most affected by AMR—patients and their families—are often the ones who lack that awareness and rely on understanding its consequences. -
bioMérieux and Vall d'Hebron Join Forces Against Infectious Diseases
bioMérieux announces a new strategic research partnership with Vall d'Hebron, one of Spain's largest and most prestigious healthcare institutions. This collaboration aims to advance research and development in the areas of infectious diseases, data surveillance, and laboratory automation.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19